Cellectis announced that it has drawn down the second tranche of 15 million under the credit facility agreement for up to 40 million entered into with the European Investment Bank (the EIB) on December 28, 2022. Tranche B is expected to be disbursed by the EIB by January 25, 2024. The Company plans to use the proceeds of Tranche B towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, and UCART123.

As a condition to the disbursement of Tranche B the Company issued 1,460,053 warrants to the benefit of the EIB, in accordance with the terms of the 14 resolution of the shareholders' meeting held on June 27, 2023 and articles L. 228-91 and seq. of the French Commercial Code . Each Tranche B Warrant allows the EIB to subscribe for one ordinary share of the Company, at a price of 2.53, corresponding to 99% of the volume-weighted average price of the Company's ordinary shares over the last 3 trading days preceding the decision of the board of directors of the Company to issue the Tranche B Warrants.

The total number of shares issuable upon exercise of the Tranche B Warrants represents circa 2% of the Company's outstanding share capital as at their issuance date.